Sujay Kango has sold stock and made no open-market buys since Dec 2016

Sujay Kango is a biotechnology executive and seasoned commercial leader with more than 26 years of experience in the pharmaceutical and biotechnology sectors.( He served as EVP and Chief Commercial Officer at Acceleron Pharma Inc. from 2018 to 2021, during which time the company advanced and commercialized key assets prior to its acquisition by Merck & Co. in a transaction valued at over $11.5 billion.( As a corporate insider at Acceleron Pharma (XLRN), Kango executed multiple share sales in 2021 in his capacity as EVP, Chief Commercial Officer, as reflected in Form 4 filings and insider trading records.(

Kango’s career includes senior commercial and leadership roles across multiple biopharmaceutical companies, and he has been responsible for the launch and growth of over five blockbuster products, including Reblozyl, Nexavar, Kyprolis, Peg-Intron, and Remicade.( Beyond his C‑suite roles, he has served on the boards of MEI Pharma, Infinity Pharmaceuticals, Adanate, Inc., and Dianthus Therapeutics, where he is recognized as a seasoned commercial leader and strategic advisor.( He also served as President and Chief Executive Officer of Tmunity Therapeutics, a clinical-stage CAR‑T therapy company later acquired by Gilead Sciences.( Kango holds both a B.S. in Microbiology and an M.B.A. from McNeese State University, providing a combined scientific and business foundation for his commercial and executive responsibilities in the biotech industry.(

Written by Perplexity from public sources.